RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsPwC reports that for 2023 "the need to invest to achieve transformation will remain unparalleled. Achieving scale to deliver shareholder value is imperative. We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot but see the potential for larger deals in the second half of the year."
https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html